Canadian (TSX) Soft Drinks Industry Analysis

Industry Valuation and Performance

Has the Canadian Soft Drinks Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 29 May 2026	CA$127.8m	CA$36.9m	-CA$40,561,967.00	n/a	-3.1x	3.5x
Sun, 26 Apr 2026	CA$167.5m	CA$37.5m	-CA$40,642,658.00	n/a	-4.1x	4.5x
Tue, 24 Mar 2026	CA$173.5m	CA$37.5m	-CA$40,642,658.00	n/a	-4.3x	4.6x
Thu, 19 Feb 2026	CA$185.2m	CA$36.2m	-CA$41,912,023.00	n/a	-4.4x	5.1x
Sat, 17 Jan 2026	CA$219.4m	CA$33.3m	-CA$44,599,604.00	n/a	-4.9x	6.6x
Mon, 15 Dec 2025	CA$180.9m	CA$33.3m	-CA$44,599,604.00	n/a	-4.1x	5.4x
Wed, 12 Nov 2025	CA$178.1m	CA$33.4m	-CA$54,181,800.00	n/a	-3.3x	5.3x
Fri, 10 Oct 2025	CA$194.7m	CA$33.4m	-CA$54,181,800.00	n/a	-3.6x	5.8x
Sun, 07 Sep 2025	CA$125.0m	CA$32.1m	-CA$22,588,090.00	n/a	-5.5x	3.9x
Tue, 05 Aug 2025	CA$100.1m	CA$32.0m	-CA$26,707,681.00	n/a	-3.7x	3.1x
Thu, 03 Jul 2025	CA$108.9m	CA$32.0m	-CA$26,707,681.00	n/a	-4.1x	3.4x
Sat, 31 May 2025	CA$86.2m	CA$33.2m	-CA$31,721,761.00	n/a	-2.7x	2.6x
Mon, 28 Apr 2025	CA$79.3m	CA$32.9m	-CA$20,217,301.00	n/a	-3.9x	2.4x
Wed, 26 Mar 2025	CA$84.0m	CA$32.9m	-CA$20,217,301.00	n/a	-4.2x	2.6x
Fri, 21 Feb 2025	CA$89.4m	CA$31.1m	-CA$16,024,500.00	n/a	-5.6x	2.9x
Sun, 19 Jan 2025	CA$80.1m	CA$31.6m	-CA$11,927,314.00	n/a	-6.7x	2.5x
Tue, 17 Dec 2024	CA$71.6m	CA$31.6m	-CA$11,927,314.00	n/a	-6x	2.3x
Thu, 14 Nov 2024	CA$78.5m	CA$31.6m	-CA$11,927,314.00	n/a	-6.6x	2.5x
Sat, 12 Oct 2024	CA$5.6b	CA$2.6b	CA$96.8m	52.4x	58.2x	2.2x
Mon, 09 Sep 2024	CA$5.1b	CA$2.5b	CA$94.4m	47.2x	54.4x	2x
Wed, 07 Aug 2024	CA$5.0b	CA$2.5b	CA$96.4m	44.1x	51.9x	2x
Fri, 05 Jul 2024	CA$4.8b	CA$2.5b	CA$95.1m	43.5x	50.6x	1.9x
Sun, 02 Jun 2024	CA$5.0b	CA$2.5b	CA$95.0m	45.5x	52.9x	2x
Tue, 30 Apr 2024	CA$4.2b	CA$2.5b	CA$60.3m	47.5x	70.5x	1.7x
Thu, 28 Mar 2024	CA$4.1b	CA$2.4b	CA$59.7m	45.9x	68.2x	1.7x
Sat, 24 Feb 2024	CA$3.5b	CA$2.4b	CA$58.0m	39.7x	60.4x	1.4x
Mon, 22 Jan 2024	CA$3.2b	CA$3.2b	CA$79.3m	19.7x	40.7x	1x
Wed, 20 Dec 2023	CA$3.4b	CA$3.1b	CA$78.2m	21x	43.4x	1.1x
Fri, 17 Nov 2023	CA$3.2b	CA$3.2b	CA$82.4m	19.2x	39.2x	1x
Sun, 15 Oct 2023	CA$3.0b	CA$3.2b	CA$29.2m	24.8x	103.6x	1x
Tue, 12 Sep 2023	CA$3.3b	CA$3.1b	CA$28.3m	27.6x	118.3x	1.1x
Thu, 10 Aug 2023	CA$3.1b	CA$3.1b	-CA$32,400,023.00	53x	-96.2x	1x
Sat, 08 Jul 2023	CA$2.9b	CA$3.1b	-CA$66,284,184.00	49.5x	-44.2x	0.9x
Mon, 05 Jun 2023	CA$3.0b	CA$3.1b	-CA$68,650,763.00	49.2x	-43.2x	0.9x

Current Industry PE

There are only 3 companies in the Canadian Soft Drinks industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.

Past Earnings Growth

The earnings for companies in the Soft Drinks industry have improved over the last three years.
Meanwhile revenues for these companies have declined 77% per year.
This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Canadian Soft Drinks compare with similar industries?


CA Market	0.08%
Consumer Staples	-0.45%
Beverage	-2.16%
Soft Drinks	-6.00%
Distillers and Wine Makers	0.88%
Brewers	-4.60%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

	Company	Last Price	7D	1Y	Valuation
	GURU GURU Organic Energy	CA$3.64	0.8% +CA$903.5k	98.9%	PS3.1x

Company

Last Price

Valuation

GURU GURU Organic Energy

CA$3.64

0.8%
+CA$903.5k

98.9%

PS3.1x

HYTN Innovations Inc Expands Drug Establishment Licence to Include Active Pharmaceutical Ingredients and Pharmaceutical Oils

HYTN Innovations Inc. had its Health Canada Drug Establishment Licence (DEL) amended following a comprehensive Good Manufacturing Practices (GMP) inspection of its Kelowna, British Columbia Facility. Under the amended licence, issued by Health Canada, HYTN is now authorized to fabricate, package, and label non-sterile Active Pharmaceutical Ingredients (API) in both solid and non-solid forms, and adds Pharmaceutical Oil as an authorized finished dosage form. The updated scope of the license expands the Company's GMP manufacturing activities and supports its ability to service both pharmaceutical and cannabinoid supply chains subject to applicable product-specific, customer-specific, import, release, and jurisdictional requirements. The amended licence, together with its previously announced Cannabis Drug Licence, Cannabis Processing Licence, and expanded DEL dosage form authorizations, permits additional regulated manufacturing activities at HYTN’s Kelowna facility. These activities may support HYTN’s participation in regulated drug-development and pharmaceutical manufacturing programs involving cannabinoid-derived inputs and finished dosage forms, where applicable product-specific, customer-specific, import, release, drug control, and jurisdictional requirements are satisfied. The amendment represents a progression from manufacturing cannabis products to GMP specifications toward additional pharmaceutical manufacturing activities authorized under the DEL. Canada has been added to the European Commission’s list of third countries whose regulatory framework for active substances has been assessed as equivalent for purposes of EU active substance importation. As a result, certain EU written confirmation requirements applicable to active substances imported from non-listed countries may be waived for Canadian-manufactured APIs, subject in all cases to applicable EU, importer, product-specific, and jurisdictional requirements. This does not constitute automatic EU market access, product approval, or authorization to import any specific product in the European Union. The amended DEL will provide greater flexibility to support its regulated activities in domestic and international markets, including the manufacture of cannabinoid-based APIs and finished dosage forms where permitted. HYTN continues to supply products into federally regulated medical and pharmaceutical markets in Germany, the United Kingdom, and Australia, while evaluating opportunities that align with its GMP manufacturing platform, licence portfolio, and quality systems. The amended DEL does not itself announce or imply any new contract, customer, purchase order, product approval, revenue, or market authorization. Export, import, sale, release, or use of any product remains subject to applicable customer, importer, product-specific, drug control, quality, and jurisdictional requirements.

Canadian (TSX) Soft Drinks Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

GURU Organic Energy Corp. to Report Q2, 2026 Results on Jun 11, 2026

New major risk - Share price stability

HYTN Innovations Inc Expands Drug Establishment Licence to Include Active Pharmaceutical Ingredients and Pharmaceutical Oils

New major risk - Negative shareholders equity

No independent directors